Immix Biopharma shares surge 29.86% premarket after 75% CR rate in NXC-201 Phase 2 trial for AL amyloidosis.

Immix Biopharma surged 29.86% in premarket trading following the presentation of Phase 2 NXC-201 clinical results at ASH 2025, showing a 75% complete response rate (15/20 patients) and potential for 95% future responses based on MRD negativity. The data, highlighting low toxicity and organ responses in 70% of patients, underscores NXC-201’s potential as a transformative therapy for relapsed/refractory AL Amyloidosis, a market with significant unmet need. The company also announced plans for a 2026 Biologics License Application, reinforcing investor optimism. These developments, combined with a $100 million equity raise to fund NXC-201’s development, likely drove the sharp premarket increase.